替代激活巨噬细胞促进急性肝损伤坏死消退
该研究在小鼠对乙酰氨基酚(APAP)诱导的急性肝损伤(ALI)模型中,于肝坏死建立后静脉输注不同表型的骨髓来源巨噬细胞(BMDMs),发现替代激活巨噬细胞(AAMs)可减少肝细胞坏死、HMGB1转位和中性粒细胞浸润,并促进肝细胞与内皮增殖、降低循环促炎因子。健康志愿者来源的临床级人AAMs在免疫健全APAP-ALI小鼠中部分重现疗效,提示其作为细胞治疗候选的转化潜力。
要点
- AAMs在APAP-ALI小鼠中减少肝细胞坏死、HMGB1转位及中性粒细胞浸润。
- AAMs促进肝细胞和内皮增殖,并在24小时内降低多种循环促炎因子。
- 临床级人AAMs在免疫健全APAP-ALI小鼠中部分重现治疗 efficacy。
核心结论
- AAMs在实验性APAP-ALI模型中具有细胞治疗价值。
- 人AAMs值得进一步评估作为APAP过量且已建立肝损伤患者的潜在细胞治疗。
研究设计与样本
- 研究在小鼠APAP诱导的ALI模型中测试同基因原代骨髓来源巨噬(BMDMs)作为细胞治疗。
- 在肝坏死建立后静脉输注多种表型不同的BMDMs,评估其对损伤、炎症、免疫和再生的影响。
- 采用体内吞噬实验检测注射后AAMs的表型和功能。
- 将健康志愿者来源的原代人AAMs用于免疫健全APAP-ALI小鼠评估。
主要发现
- BMDMs在给药后4小时内迅速定位至肝脏和脾脏。
- 注射AAMs特异性减少APAP-ALI后的肝细胞坏死、HMGB1转位和浸润中性粒细胞。
- AAMs输注刺激肝细胞和内皮增殖,并在24小时内降低多种循环促炎因子水平。
- AAMs在体外和注射后损伤肝组织中均显示高吞噬活性。
- AAMs治疗小鼠中宿主浸润性Ly6Chi巨噬细胞减少,表明与宿主先天免疫系统存在交互。
临床怎么用
- 目前仅为实验模型结果,尚不能直接用于临床实践。
- 人AAMs可作为APAP过量后已建立肝损伤患者的潜在细胞治疗方向进一步研究。
局限性
- 疗效主要在小鼠APAP-ALI模型中验证,人AAMs仅在免疫健全小鼠中部分重现疗效。
- 原文未报告临床患者数据或长期安全性结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIM: Following acetaminophen (APAP) overdose, acute liver injury (ALI) can occur in patients that present too late for N-acetylcysteine treatment, potentially leading to acute liver failure, systemic inflammation, and death. Macrophages influence the progression and resolution of ALI due to their innate immunological function and paracrine activity. Syngeneic primary bone marrow-derived macrophages (BMDMs) were tested as a cell-based therapy in a mouse model of APAP-induced ALI (APAP-ALI). METHODS: Several phenotypically distinct BMDM populations were delivered intravenously to APAP-ALI mice when hepatic necrosis was established, and then evaluated based on their effects on injury, inflammation, immunity, and regeneration. In vivo phagocytosis assays were used to interrogate the phenotype and function of alternatively activated BMDMs (AAMs) post-injection. Finally, primary human AAMs sourced from healthy volunteers were evaluated in immunocompetent APAP-ALI mice. RESULTS: BMDMs rapidly localised to the liver and spleen within 4 h of administration. Injection of AAMs specifically reduced hepatocellular necrosis, HMGB1 translocation, and infiltrating neutrophils following APAP-ALI. AAM delivery also stimulated proliferation in hepatocytes and endothelium, and reduced levels of several circulating proinflammatory cytokines within 24 h. AAMs displayed a high phagocytic activity both in vitro and in injured liver tissue post-injection. Crosstalk with the host innate immune system was demonstrated by reduced infiltrating host Ly6Chi macrophages in AAM-treated mice. Importantly, therapeutic efficacy was partially recapitulated using clinical-grade primary human AAMs in immunocompetent APAP-ALI mice, underscoring the translational potential of these findings. CONCLUSION: We identify that AAMs have value as a cell-based therapy in an experimental model of APAP-ALI. Human AAMs warrant further evaluation as a potential cell-based therapy for APAP overdose patients with established liver injury. LAY SUMMARY: After an overdose of acetaminophen (paracetamol), some patients present to hospital too late for the current antidote (N-acetylcysteine) to be effective. We tested whether macrophages, an injury-responsive leukocyte that can scavenge dead/dying cells, could serve as a cell-based therapy in an experimental model of acetaminophen overdose. Injection of alternatively activated macrophages rapidly reduced liver injury and reduced several mediators of inflammation. Macrophages show promise to serve as a potential cell-based therapy for acute liver injury.
引用
- Starkey Lewis P, Campana L, Aleksieva N, et al. Alternatively activated macrophages promote resolution of necrosis following acute liver injury. J Hepatol. 2020. PMID: 32169610. doi:10.1016/j.jhep.2020.02.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。